Medical Cannabis and Epilepsy: New Hope for Seizure Management
The potential of medical cannabis in treating epilepsy has become an important area of research, especially for those with severe, drug-resistant forms of the condition. Epilepsy affects over 600,000 people in the UK, with up to 30% unable to achieve seizure control through conventional medications alone. Here’s where cannabinoids—particularly cannabidiol (CBD)—are offering new hope.
Why CBD for Epilepsy?
CBD, a non-psychoactive compound in cannabis, has shown significant promise in reducing seizures. By interacting with the body’s endocannabinoid system, CBD can help reduce brain hyperactivity, which is linked to seizures. Research, including the well-known GWPCARE study, shows that CBD can reduce seizure frequency by up to 50% for some patients. It’s also been approved in the UK to treat rare, severe types of epilepsy, such as Dravet syndrome and Lennox-Gastaut syndrome, which often resist other treatments.
How Medical Cannabis Is Administered for Epilepsy
Medical cannabis for epilepsy is generally prescribed in oil form, making it easy to control doses and ensure accurate delivery. Patients are typically prescribed CBD-dominant products, which minimise psychoactive effects and allow for a higher degree of seizure management. The dosage is tailored based on the patient’s needs and their response to treatment, highlighting the importance of close consultation with a medical professional experienced in cannabis therapies.
How Mamedica Can Help
At Mamedica, we’re dedicated to supporting patients in exploring the potential of medical cannabis. With a commitment to responsible information and patient care, we aim to help individuals navigate this promising treatment option for epilepsy.
If you would like to start your journey with Mamedica, you can check your eligibility here.